{"organizations": [], "uuid": "da54e2aa72646014648f51f382b46871f93d081b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180417.html", "section_title": "Archive News &amp; Video for Tuesday, 17 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/health-sellas/drugmaker-sellas-discloses-n-y-federal-opioid-probe-into-doctors-idUSL1N1RV00B", "country": "US", "domain_rank": 408, "title": "Drugmaker Sellas discloses N.Y. federal opioid probe into doctors", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.004, "site_type": "news", "published": "2018-04-18T08:10:00.000+03:00", "replies_count": 0, "uuid": "da54e2aa72646014648f51f382b46871f93d081b"}, "author": "Nate Raymond", "url": "https://www.reuters.com/article/health-sellas/drugmaker-sellas-discloses-n-y-federal-opioid-probe-into-doctors-idUSL1N1RV00B", "ord_in_thread": 0, "title": "Drugmaker Sellas discloses N.Y. federal opioid probe into doctors", "locations": [], "entities": {"persons": [{"name": "drugmaker sellas", "sentiment": "negative"}, {"name": "sellas", "sentiment": "none"}], "locations": [{"name": "n.y.", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "manhattan", "sentiment": "none"}], "organizations": [{"name": "sellas life sciences group inc", "sentiment": "negative"}, {"name": "westlaw", "sentiment": "none"}, {"name": "u.s. securities and exchange commission", "sentiment": "none"}, {"name": "galena biopharma inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Sellas Life Sciences Group Inc, which last year resolved a U.S. probe into allegations the drugmaker paid kickbacks to doctors to prescribe opioids, says federal prosecutors in Manhattan have issued it a subpoena seeking records related to specific physicians.\nSellas, formerly known as Galena Biopharma Inc, previously marketed the fentanyl-based pain medication Abstral. The company disclosed the subpoena in a filing with the U.S. Securities and Exchange Commission on Friday.\nTo read the full story on Westlaw Practitioner Insights, click here: bit.ly/2EUF1ar\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://bit.ly/2EUF1ar", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-18T08:10:00.000+03:00", "crawled": "2018-04-18T18:35:32.008+03:00", "highlightTitle": ""}